Measures of kidney function
|
No events/no at risk
|
P-years
|
Rate/1000 p-years
|
Model 1
|
Model 2
|
Model 3
|
---|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
---|
UACR
|
eGFR
| | | | | | | | | |
< 30
|
≥ 60
|
61/5703
|
27414.3
|
2.2 (1.7–2.9)
|
1 (reference)
| |
1 (reference)
| |
1 (reference)
| |
< 30
|
< 60
|
13/537
|
2698.0
|
4.8 (2.8–8.3)
|
1.76 (0.95–3.26)
|
0.070
|
1.64 (0.88–3.06)
|
0.117
|
1.59 (0.86–2.97)
|
0.142
|
≥ 30
|
≥ 60
|
62/2508
|
11791.2
|
5.3 (4.1–6.7)
|
2.30 (1.61–3.28)
|
< 0.001
|
1.80 (1.24–2.61)
|
0.002
|
1.79 (1.23–2.60)
|
0.002
|
≥ 30
|
< 60
|
20/422
|
2021.5
|
9.9 (6.4–15.3)
|
3.66 (2.17–6.17)
|
< 0.001
|
2.61 (1.50–4.55)
|
0.001
|
2.54 (1.45–4.43)
|
0.001
|
- Model 1 adjusted for age, sex, race, and treatment arm; model 2, model 1 variables plus duration of diabetes, hemoglobin A1C, cigarette smoking, alcohol intake; body mass index, total-to-HDL cholesterol, systolic BP, use of BP-lowering medications, atrial fibrillation; history of CVD (excluding stroke) at baseline; model 3, model 2 variables plus use of antiplatelet agents (including aspirin)/ anticoagulants, diuretics, ACEI/ARB
- ACEI indicates angiotensin-converting enzyme inhibitors, ARB angiotensin-II receptor blockers, BP blood pressure, CI confidence interval, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, HR hazard ratio, p-years person-years, UACR urine albumin-creatinine ratio